Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
China (Chinese)
Profile Icon Profile Icon
登录/注册 UserName
产品

解决方案

发现&学习

资源&工具

Support

Search icon Search icon
Close Menu
      Alert Icon
      BV421 Biosimilar Anti-Human CD20

      BD Horizon™ BV421 Biosimilar Anti-Human CD20

      克隆 Obinutuzumab297.rMAb (also known as Obinutuzumab N297A Biosimilar.rMAb)

      (RUO)
      查看所有格式
      BV421 Biosimilar Anti-Human CD20
      Flow cytometric analysis of Human CD20 (Obinutuzumab Biosimilar) expression on Human peripheral blood lymphocytes. Human whole blood was stained with PE Mouse Anti-Human CD19 antibody (Cat. No. 555413) and with either BD OptiBuild™ BV421 Human IgG1 (N297A), κ Isotype Control (Cat. No. 756231; Left Plot) or BD Horizon™ BV421 Biosimilar Anti-Human CD20 (Obinutuzumab Biosimilar) antibody (Cat. No. 570970/571041; Right Plot). The erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). The bivariate pseudocolor density plot showing the correlated expression of CD20 (Obinutuzumab Biosimilar) [or Ig Isotype control staining] versus CD19 was derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ Software.
      BV421 Biosimilar Anti-Human CD20
      Flow cytometric analysis of Human CD20 (Obinutuzumab Biosimilar) expression on Human peripheral blood leukocytes. Human whole blood was stained with BD OptiBuild™ BV421 Human IgG1 (N297A), κ Isotype Control (Cat. No. 756231; Left Plot) or BD Horizon™ BV421 Biosimilar Anti-Human CD20 (Obinutuzumab Biosimilar) antibody (Cat. No. 570970/571041; Right Plot). The erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). The bivariate pseudocolor density plot showing the correlated expression of CD20 (Obinutuzumab Biosimilar) [or Ig Isotype control staining] versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of intact leukocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ Software.
      BV421 Biosimilar Anti-Human CD20 BV421 Biosimilar Anti-Human CD20
      Flow cytometric analysis of Human CD20 (Obinutuzumab Biosimilar) expression on Human peripheral blood lymphocytes. Human whole blood was stained with PE Mouse Anti-Human CD19 antibody (Cat. No. 555413) and with either BD OptiBuild™ BV421 Human IgG1 (N297A), κ Isotype Control (Cat. No. 756231; Left Plot) or BD Horizon™ BV421 Biosimilar Anti-Human CD20 (Obinutuzumab Biosimilar) antibody (Cat. No. 570970/571041; Right Plot). The erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). The bivariate pseudocolor density plot showing the correlated expression of CD20 (Obinutuzumab Biosimilar) [or Ig Isotype control staining] versus CD19 was derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ Software.
      Flow cytometric analysis of Human CD20 (Obinutuzumab Biosimilar) expression on Human peripheral blood leukocytes. Human whole blood was stained with BD OptiBuild™ BV421 Human IgG1 (N297A), κ Isotype Control (Cat. No. 756231; Left Plot) or BD Horizon™ BV421 Biosimilar Anti-Human CD20 (Obinutuzumab Biosimilar) antibody (Cat. No. 570970/571041; Right Plot). The erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). The bivariate pseudocolor density plot showing the correlated expression of CD20 (Obinutuzumab Biosimilar) [or Ig Isotype control staining] versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of intact leukocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ Software.
      商品详情
      Down Arrow Up Arrow


      BD Horizon™
      B1; Bp35; LEU-16; MS4A1
      Human (QC Testing)
      Human IgG1, κ
      Human CD20
      Flow cytometry (Routinely Tested)
      5 µl/test
      931
      Aqueous buffered solution containing ≤0.09% sodium azide.
      RUO


      准备和存储

      The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions and unconjugated antibody and free dye were removed. Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
      显示较多信息 blue down arrow 显示较少信息 blue up arrow

      推荐的实验流程

           BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation).  When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells.   However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls.  It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

           For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

      显示较多信息 blue down arrow 显示较少信息 blue up arrow

      商品通知

      1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
      3. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
      4. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
      5. An isotype control should be used at the same concentration as the antibody of interest.
      6. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
      7. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
      8. For U.S. patents that may apply, see bd.com/patents.
      显示较多信息 blue down arrow 显示较少信息 blue up arrow
      571041 Rev. 1
      抗体详情
      Down Arrow Up Arrow
      Obinutuzumab297.rMAb

      The Obinutuzumab297.rMAb (also known as, Obinutuzumab N297A Biosimilar.rMAb) is a research grade humanized recombinant human IgG1, kappa antibody that specifically recognizes the extracellular domain of human CD20 similarly to the therapeutic Obinutuzumab antibody. The Obinutuzumab297.rMAb uses the same variable region sequences as Obinutuzumab, combined with constant region sequences derived from consensus sequences of human IgG1, kappa. The asparagine at position 297 of the constant heavy chain has been replaced with alanine (N297A) to further reduce Fc receptor interactions of this reagent. Obinutuzumab triggers target cell death through multiple mechanisms including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis. The therapeutic Obinutuzumab has been approved to treat human B cell malignancies, autoimmune disorders, and transplant rejection. CD20 is a 33-37 kDa, unglycosylated four-transmembrane phosphoprotein with a cytoplasmic N-terminus and C-terminus that is encoded by MS4A1 (Membrane-spanning 4-domains, subfamily A, member 1). CD20 is expressed on pre-B-cells, naive and activated B cells, memory B cells, and at lower levels on a small subset of T cells but is absent from plasmablasts and plasma cells. It is also expressed on most malignant B cells and CD20-positive T-cell lymphomas. CD20 functions in mediating calcium transport and B cell activation, differentiation, and survival.

         The Obinutuzumab297.rMAb is intended for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.

      571041 Rev. 1
      格式详情
      Down Arrow Up Arrow
      BV421
      The BD Horizon Brilliant Violet™ 421 (BV421) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye has an excitation maximum (Ex Max) of 407-nm and an emission maximum (Em Max) at 423-nm. Driven by BD innovation, BV421 is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 420-nm (e.g., a 431/28-nm or 450/50-nm bandpass filter). BV421 is an ideal alternative for V450 as it is approximately ten times brighter with less spillover into the BV510/V500 detector. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
      altImg
      BV421
      Violet 405 nm
      407 nm
      423 nm
      571041 Rev.1
      报价单和参考
      Down Arrow Up Arrow
      View product citations for antibody "571041" on CiteAb

      研发参考 (5)

      1. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol. 1992; 40:259-263. (Biology).
      2. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century.. Nat Rev Drug Discov. 2003; 2(1):52-62. (Biology). 查看参考
      3. Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on asubpopulation of human T lymphocytes. Cytometry. 1993; 14:196-204. (Biology).
      4. Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.. Adv Ther. 2017; 34(2):324-356. (Biology). 查看参考
      5. Zola H, Swart B, Nicholson I, Voss E. CD20. In: Zola H. Leukocyte and stromal cell molecules : the CD markers. Hoboken, N.J.: Wiley-Liss; 2007:72.
      查看所有文件 (5) 查看更少内容
      571041 Rev. 1

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.